An Analysis of the Results of the BETH Study
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study
Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study, which compared chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in patients with HER2-positive breast cancer.
Clinical Pearls:
- Although the results of the trial were negative, the results did show that THC therapy is as good, if not better, than ACTH therapy
- The results of the BETH study are consistent with other studies
- The era of adjuvant bevacizumab for breast cancer has come and gone unless there is a way to select patients who will benefit
- Some biomarkers are in the works that may be able to be used to select patients who will benefit from bevacizumab
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
